Don't forget to join @vigeotx.bsky.social
COO Jing Watnick speaking at the
#GBM summit in Boston at 1:30 EDT today. Dr. Watnick will speak on our Ph1/2 in GBM as well as the future use of #VT1021 in attacking the roots of #Neuroinflammatory disease. #glioblastoma #neurodegenerativedisease

Don't miss the #VT1021 update from @vigeotx.bsky.social COO Jing Watnick at the #GBMSummit in Boston MA this week. Dr. Watnick will give an update on the #VT1021 Ph1/2 program in #GBM as well as potential future use of #VT1021 in Neuro-inflammatory disease #glioblastoma #neuroinflammatorydisease

Great story on GBM patient at Cleveland Clinic.

www.wkyc.com/article/news...

Dr. Suming Wang of Vigeo Therapeutics presented a poster at the Crohn's and Colitis Congress in Las Vegas NV studying VT1021 efficacy in IBD models in mice. #VT1021 #TSP1 #IBD #crohnsdisease #cccongress24

vigeotx.com/wp-content/u...

“We love you, Chita.” Chita Rivera’s death on Tuesday at 91 inspired an outpouring of tributes from fans, elected officials and stars of stage and screen. She was recalled as a pathbreaking triple-threat who left a huge legacy in musical theater and dance.

Goodbye to the anti-amyloid Alzheimer's drug Aduhelm, and frankly, good riddance:

www.science.org/content/blog...

So proud of the @vigeotx.bsky.social Team on the publication of our First in Human Phase 1 study with VT1021 in #NatureCommunicationsMedicine This paper is a great achievement showing the power of VT1021 treating solid tumors #CD36 #CD47 #VT1021 #NaturePortfolio
rdcu.be/dvUw8

Wrote this back in December. Mastadon wasn't it. Post wasn't quite it. Maybe this is? And re-upping @adamfeuerstein.bsky.social's suggestion to use #biosky to find other biotech folks. https://www.bloomberg.com/opinion/articles/2022-12-24/science-twitter-needs-a-new-home-and-mastodon-s-not-it

Happy Fourth! Eat a hot dog.

The biotech scorecard for the third quarter: 15 stock-moving events to watch #biosky

https://www.statnews.com/2023/07/03/biotech-scorecard-third-quarter-2023/

Akero’s $AKRO treatment for NASH falls short in cirrhosis study

Liver fibrosis improvement 24% for EFX vs 14% placebo, not stat sig. But NASH resolution 63% vs 26%. More details and Akero comments in story below.

www.statnews.com/2023/10/10/n...

High vaccine protection against moderate and severe Covid in children and teens throughout the pandemic acpjournals.org/doi/10.7326/...

And lower risk of cardiac complications among the vaccinated group during Omicron periods

Here is why immunizations are important.

Chicken pox comes back as shingles.

CMV comes back as severe colitis.

HPV comes back as cancer.

EBV increasingly looks like it comes back as MS.

What is SARS CoV-2 coming back as? We know it sequesters in all sorts of tissues.

Obesity drug challengers will struggle to break into plus-sized market

https://on.ft.com/4aNFBGW

GSK agrees to buy respiratory medicine specialist Aiolos Bio for $1.4bn

https://on.ft.com/3RYXdr4

Vigeo Therapeutics is now on @bsky.app our handle is @vigeotx.bsky.social